A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC)

Trial Profile

A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC)

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Ocular Therapeutix
  • Most Recent Events

    • 07 Dec 2016 Status changed to completed.
    • 06 Jun 2016 According to an Ocular Therapeutix media release, the company announced topline results from this trial evaluating the safety and efficacy of sustained release dexamethasone.
    • 06 Jun 2016 Primary endpoint (Ocular itching at day 7 following insertion) has not been met, according to Ocular Therapeutix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top